0001628280-21-000060.txt : 20210105
0001628280-21-000060.hdr.sgml : 20210105
20210105160327
ACCESSION NUMBER: 0001628280-21-000060
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210102
FILED AS OF DATE: 20210105
DATE AS OF CHANGE: 20210105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Erlander Mark
CENTRAL INDEX KEY: 0001651537
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35558
FILM NUMBER: 21505377
MAIL ADDRESS:
STREET 1: C/O TROVAGENE, INC.
STREET 2: 11055 FLINTKOTE AVENUE, SUITE A
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cardiff Oncology, Inc.
CENTRAL INDEX KEY: 0001213037
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 272004382
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11055 FLINTKOTE AVENUE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-952-7570
MAIL ADDRESS:
STREET 1: 11055 FLINTKOTE AVENUE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Trovagene, Inc.
DATE OF NAME CHANGE: 20130304
FORMER COMPANY:
FORMER CONFORMED NAME: TrovaGene Inc.
DATE OF NAME CHANGE: 20110830
FORMER COMPANY:
FORMER CONFORMED NAME: XENOMICS INC
DATE OF NAME CHANGE: 20040719
4
1
wf-form4_160988059527289.xml
FORM 4
X0306
4
2021-01-02
0
0001213037
Cardiff Oncology, Inc.
CRDF
0001651537
Erlander Mark
C/O CARDIFF ONCOLOGY, INC.
11055 FLINTKOTE AVE
SAN DIEGO
CA
92121
0
1
0
0
Chief Executive Officer
Common Stock
2021-01-02
4
M
0
260
0
A
13629
D
Common Stock
2021-01-02
4
F
0
113
0
D
13516
D
Restricted Stock Units
2021-01-02
4
M
0
260
0
D
Common Stock
260.0
0
D
Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017.
The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 113 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021.
Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock.
On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4.
/s/ Mark Erlander
2021-01-05